Video

Urology Times 50 Innovations Series: Dr. Kelvin Moses on sipuleucel-T for mCRPC

Author(s):

Urology Times staff

“In using an immune therapy approach, and using your own cells, it's very innovative in the mechanism that it works,” says Kelvin A. Moses, MD, PhD.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected

      Urology Times® is celebrating its 50th anniversary in 2022. To mark the occasion, we are high-lighting 50 of the top innovations and developments that have transformed the field of urology over the past 50 years. In this installment, Kelvin A. Moses, MD, PhD, discusses the prostate cancer treatment sipuleucel-T (Provenge). Moses is an associate professor of urology and fellowship director of urologic oncology at Vanderbilt University Medical Center, Nashville, Tennessee.

      Related Videos
      Man talking with doctor | Image Credit: © Khunatorn - stock.adobe.com
      Stephen J. Freedland, MD, on the benefits of mCRPC treatments translating to the real world
      Preston Sprenkle, MD, highlights trial of TULSA vs radical prostatectomy
      Preston Sprenkle, MD, highlights trial of TULSA vs radical prostatectomy
      Sam Chang, MD, shares updated data on nogapendekin alfa inbakicept in NMIBC
      Sam Chang, MD, shares updated data on nogapendekin alfa inbakicept in NMIBC
      Man talking with a doctor | Image Credit: © Pcess609 - stock.adobe.com
      Expert discusses the relationship between RCTs and real-world efficacy of prostate cancer treatments
      Study data point to gender disparities in oncology research citations
      Study data point to gender disparities in oncology research citations
      Nitin Yerram, MD, highlights trial of 177Lu-PSMA-617 in localized prostate cancer
      Nitin Yerram, MD, highlights trial of 177Lu-PSMA-617 in localized prostate cancer
      Neeraj Agarwal, MD, shares key takeaways from TALAPRO-2
      Neeraj Agarwal, MD, shares key takeaways from TALAPRO-2
      Betty Wang, MD, discusses studies from the 2025 EAU meeting
      Betty Wang, MD, recaps 3 key urologic cancer studies from EAU 2025
      Neeraj Agarwal, MD, on the safety profile of talazoparib/enzalutamide in mCRPC
      Neeraj Agarwal, MD, on the safety profile of talazoparib/enzalutamide in mCRPC
      Rana McKay, MD, on persistence and adherence to relugolix for prostate cancer
      Rana McKay, MD, on persistence and adherence to relugolix for prostate cancer
      Related Content
      Artificial urinary sphincter for SUI shows safety, efficacy in prospective study
      May 9th 2025

      Artificial urinary sphincter for SUI shows safety, efficacy in prospective study

      Melissa Kaufman, MD, PhD, FACS Hannah Clarke
      "This trial will be the benchmark for research reporting in the future," says Melissa R. Kaufman, MD, PhD, FACS.
      Speaking of Urology: Melissa Kaufman, MD, on AUA’s new guideline on genitourinary syndrome of menopause
      April 28th 2025

      Speaking of Urology: Melissa Kaufman, MD, on AUA’s new guideline on genitourinary syndrome of menopause

      Melissa Kaufman, MD, PhD, FACS
      In this episode, guideline chair Melissa Kaufman, MD, PhD, FACS, highlights key points from the new AUA GSM guideline and illustrates its impact for clinical management of this condition.
      Conceptual image for prostate cancer treatment, 3D illustration showing destruction of a tumor inside prostate gland | Image Credit: @ Dr_Microbe - stock.adobe.com
      May 2nd 2025

      Phase 3 trial of capivasertib in mCRPC discontinued following IDMC recommendation

      Hannah Clarke
      The committee determined that the study was unlikely to meet its dual primary end points of radiographic progression-free survival and overall survival.
      Pearls & Perspectives: Helen Bernie, DO, MPH, at AUA 2025 | Credit: Urology Times
      April 27th 2025

      Pearls & Perspectives: Helen Bernie, DO, MPH, at AUA 2025

      Amy M. Pearlman, MD Helen L. Bernie, DO, MPH
      Helen Bernie, DO, MPH, joins the show to discuss data from her Indiana University team from the floor at AUA 2025.
      ARANOTE substudy highlights benefits of darolutamide in Black men
      April 28th 2025

      ARANOTE substudy highlights benefits of darolutamide in Black men

      Benjamin P. Saylor
      The investigators reported that treatment with darolutamide reduced the risk of radiological progression or death by 49% in Black men.
      Stephen J. Freedland, MD
      April 28th 2025

      Most men in EMBARK trial recover T levels following treatment suspension

      Benjamin P. Saylor
      More than 80% of patients in both groups had a full recovery of testosterone.
      © 2025 MJH Life Sciences

      All rights reserved.